Why this matters — Three distinct ORTEX data streams have converged on XPEV simultaneously: utilisation near its 52-week peak, rising borrowing costs, and elevated options put/call activity. Together, they paint a picture of intensifying short-side pressure on the Chinese EV maker.
Utilisation at near-peak levels. Utilisation hit 95.67% on April 24 — approaching its 52-week high of 100%. Almost all available lendable shares are already out on loan. Short sellers are struggling to source new stock, which signals a fully crowded short book.
Cost to borrow climbing. CTB reached 1.41% APR on April 24. That is up 15.2% over the past week and up 102.5% over the past month. The doubling of borrowing costs reflects tightening supply in the securities lending market.
Short interest surging. Shares short rose to 50.5 million as of April 24. That is a 17.1% increase over the past month. Official FINRA data confirms 49.1 million shares short with 11.23 days to cover.
Options sentiment tilting bearish. The put/call ratio stands at 0.54. That is above the 20-day average of 0.49, with a Z-score of 1.82. The PCR has risen steadily since mid-April, signalling growing demand for downside protection.
Analyst moves lean bearish. In late March, Barclays lowered its price target to $16 — virtually in line with the current price of $16.66. Macquarie downgraded XPEV from Outperform to Neutral at the same time, cutting its target to $19 from $24. The ORTEX short score sits at 68.0 out of 100. The utilisation rank is in the 5th percentile and the short score rank is also in the 5th percentile. EPS momentum over 30 days ranks in the 84th percentile, a notable outlier. Goldman Sachs trimmed its position by 1.42 million shares as of April 15. CSOP Asset Management added 5.78 million shares in early April — a diverging institutional signal worth monitoring.
XPEV's utilisation has hit 100% at least once in the past 52 weeks. The current 95.67% reading represents a return toward that extreme. The last time utilisation reached that ceiling, the stock was equally under pressure from elevated short interest — suggesting this is a recurring pattern for the name rather than a one-off event.
See the live data behind this article on ORTEX.
Open XPEV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
